Daily non-political popular news in brief.

First antisense drug provides benefit to subset of chronic lymphocytic leukemia patients

The first "antisense" drug to be tested in chronic lymphocytic leukemia (CLL) shows benefit in a phase III clinical trial for a specific subset of patients - those who are still sensitive to a chemotherapy drug often used to treat this cancer.

Read more »

Keywords: antisense, drug, provides, benefit, subset, chronic, lymphocytic, leukemia, patients, provide, patient

« Previous | Next »

Similar news on "First antisense drug provides benefit to subset of chronic lymphocytic leukemia patients":

1. Novel MS drug shows promise in 2 lethal leukemias
   08-28-2007 · EurekAlert!
   A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia. The laboratory and animal study focused on the drug, called fingolimod. Researchers said it might help patients with advanced chronic myelogenous leukemia or acute lymphocytic leukemia, and whose cancer cells show a particular genetic change called the Philadelphia chromosome.
   Similar news · Read more »
   
2. Complete response with oblimersen combination improves survival of CLL patients
   12-09-2007 · EurekAlert!
   Relapsed chronic lymphocytic leukemia (CLL) patients who had a complete response to combination therapy that included the drug oblimersen survived significantly longer than patients treated with chemotherapy alone, a team led by researchers at the University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.
   Similar news · Read more »
   
3. Should EU patient information laws be relaxed?
   03-29-2007 · EurekAlert!
   In 2002 the European parliament voted resoundingly against allowing drug companies to provide information about their products directly to patients. However, five years on, this decision is set to be challenged again.
   Similar news · Read more »
   
4. Modifying an anti-cancer drug makes it more specific
   12-03-2007 · EurekAlert!
   Imatinib is used to treat chronic myeloid leukemia and gastrointestinal stromal tumors because they are caused by related proteins. However, this lack of specificity means imatinib also affects normal bodily functions and it has been reported to have a toxic effect on the heart in some patients. Now, researchers have modified imatinib so it inhibits the protein behind GISTs but neither inhibits the protein behind CML nor has toxic effects on the mouse heart.
   Similar news · Read more »
   
5. Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia
   06-02-2007 · EurekAlert!
   An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a phase II clinical trial at the University of Texas M. D. Anderson Cancer Center.
   Similar news · Read more »
   
6. Gene therapy protocol at UCSD activates immune system in patients with leukemia
   02-11-2008 · EurekAlert!
   A research team at the Moores Cancer Center at University of California, San Diego reports that patients with chronic lymphocytic leukemia who were treated with a gene therapy protocol began making antibodies that reacted against their own leukemia cells. The study will be published on line the week of Feb. 11-15 in the online edition of the Proceedings of the National Academy of Science.
   Similar news · Read more »
   
7. MERLIN TIMI-36 study provides new safety & efficacy data for unique anti-anginal therapy
   03-27-2007 · EurekAlert!
   Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.
   Similar news · Read more »
   
8. New weapon to fight leukemia
   08-23-2007 · EurekAlert!
   A new study indicates that the drug FTY720 prevents disease in a mouse model of two leukemias -- blast crisis chronic myeloid leukemia and acute lymphocytic leukemia -- caused by the cancer protein BCR-ABL. As the drug also induced cell lines from humans with these leukemias to die in vitro the authors suggest that FTY720 should be considered by researchers and clinicians developing new approaches to treat CML-BC and ALL.
   Similar news · Read more »
   
9. Mayo Clinic Cancer Center collaborating to find new tools to fight leukemia
   12-10-2006 · EurekAlert!
   Mayo Clinic Cancer Center, working in collaboration with Ohio State University Comprehensive Cancer Center, presented evidence Sunday that a novel regimen of three chemotherapy drugs, pentostatin, cyclophosphamide and rituximab, resulted in significant clinical response in patients with previously untreated chronic lymphocytic leukemia (CLL).
   Similar news · Read more »
   
10. MERLIN TIMI-36 study provides new safety and efficacy data for unique anti-anginal therapy
    03-27-2007 · EurekAlert!
    Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.
    Similar news · Read more »